RYBREVANT

amivantamab-vmjw · Janssen Biotech, Inc.

Drug timelines are a Plus or Pro feature.

29 regulatory and trial events tracked for RYBREVANT, covering 2021-05-21 to 2026-07-16. Get the full timeline:

Most recent: EMA Authorised: Rybrevant (amivantamab) — Janssen-Cilag International N.V.